NSPR InspireMD

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 8:00AM Eastern Time / 5:00AM Pacific Time.

A live audio webcast and replay of the presentation may be accessed for 90 days on the “News & Events” section of the company’s website at:

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit .

Investor Contacts:

Craig Shore

Chief Financial Officer

InspireMD, Inc.

888-776-6804

Webb Campbell

Gilmartin Group LLC





EN
26/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on InspireMD

 PRESS RELEASE

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid St...

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke MIAMI, July 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., following its premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA). The CGuard Prime was engineered specifically to minimize both early and late embolism risk by effectively trapping potential emb...

 PRESS RELEASE

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent Syste...

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the United States. The PMA approval is backed by best-in-class evidence from the Company’s C-GUARDIANS pivotal trial, first presented at the Leipzig Interventional...

 PRESS RELEASE

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevent...

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS. CGuard® Prime was developed incorporating extensive user feedback and optimizes deliverability and deployment of the proven CGuard stent. With its proprietary MicroNet™...

 PRESS RELEASE

InspireMD Announces Appointment of Michael Lawless as Chief Financial ...

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced the appointment of Michael Lawless, an industry veteran, as Chief Financial Officer, effective on or prior to June 30, 2025 (the “Effective Date”). On the Effective Date, Mr. Lawless will succeed Craig Shore, who has served as Chief Financial...

 PRESS RELEASE

InspireMD Reports First Quarter 2025 Financial Results

InspireMD Reports First Quarter 2025 Financial Results Management to host investor conference call today, May 9th, at 8:30am ET MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch